重庆康刻尔制药

Chongqing Kangkeer Pharmaceutical is a prominent Chinese pharmaceutical company focused on the development and production of treatments for chronic metabolic diseases, particularly diabetes. Established in 1999, the company has built a strong reputation for its expertise in sustained-release and controlled-release drug delivery technologies. Its flagship product line, marketed under the brand name "Liliang," includes high-quality generic versions of essential diabetes medications such as metformin, gliclazide, and glimepiride. Beyond its core diabetes portfolio, Kangkeer is expanding its reach into cardiovascular and digestive health therapeutic areas. The company operates advanced GMP-certified manufacturing facilities in Chongqing and maintains a dedicated research institute to drive formulation innovation. Kangkeer is recognized as a national high-tech enterprise and plays a significant role in the Chinese domestic market for oral hypoglycemic agents.